Max Delbrück Center Research Reveals ‘Quality Over Quantity’ in CAR-T Therapy, Identifying Key Factors for Low-Dose Efficacy to Enable Personalized Treatment and Cost Reduction

September 13, 2026

Max Delbrück Center for Molecular Medicine Germany

Overview

A research consortium from the Max Delbrück Center, publishing in “Nature Communications,” identified key biological factors influencing CAR-T cell therapy effectiveness at lower cell doses. The findings suggest that the absolute number of highly functional CAR-T cells could serve as a biomarker for predicting success in low-dose therapies, paving the way for improved patient outcomes, personalized treatment, and significant cost reductions. This underscores a crucial ‘quality over quantity’ principle in CAR-T therapy development.

In Depth

Key Findings

A research consortium affiliated with the Max Delbrück Center for Molecular Medicine has published pivotal findings in “Nature Communications,” identifying the critical biological factors that govern the effectiveness of CAR-T cell therapy at lower cell doses. This breakthrough suggests that the absolute number of highly functional CAR-T cells can serve as a predictive biomarker for success in low-dose therapies. This insight is poised to improve patient outcomes, enable more personalized treatment regimens, and significantly reduce the overall cost of CAR-T therapy, fundamentally shifting the paradigm from ‘quantity over quality’.

Technical / Clinical Details

Absolute Number of Functional CAR-T Cells: The study demonstrated that beyond the total quantity of CAR-T cells administered, it is the absolute number of ‘highly functional’ cells—those specifically capable of targeting and destroying tumor cells—that correlates most strongly with therapeutic success. This finding emphasizes the need for manufacturing processes to prioritize cell quality and functional capacity rather than merely maximizing cell count.
Biomarker for Predictive Success: The identification of highly functional CAR-T cell count as a potential predictive biomarker allows for more precise dosing strategies. Clinicians could potentially administer lower, more targeted doses, thereby reducing the risks of severe side effects such as cytokine release syndrome (CRS) while optimizing therapeutic efficacy for individual patients.
Personalization and Cost Reduction: Enabling effective treatment with lower cell doses directly translates to reduced manufacturing scale and, consequently, lower production costs for CAR-T therapies. This addresses a major economic barrier, making these life-saving treatments more accessible to a broader patient population. Furthermore, it supports the development of truly personalized medicine, tailoring therapies based on each patient’s unique biological response and cell characteristics.

Background & Context

CAR-T cell therapy has delivered extraordinary, often curative, outcomes in certain blood cancers. However, its widespread adoption has been hindered by prohibitively high costs, manufacturing complexities, and difficulties in predicting patient response. Historically, a higher dose was often correlated with better outcomes. This research challenges that assumption by highlighting the superior importance of cell quality and functional potency. This paradigm shift necessitates a re-evaluation of current CAR-T cell manufacturing strategies, moving beyond simple volumetric expansion to sophisticated methods that ensure the production of a high percentage of functionally superior cells.

Strategic Significance & Outlook

These research findings establish a new paradigm for CAR-T cell therapy development and clinical application, balancing efficacy with efficiency and economics. The ability to identify and optimize the number of highly functional CAR-T cells will directly influence the design and manufacturing of next-generation CAR-T products. In the future, personalized treatment strategies based on this biomarker are expected to become standard, offering patients the most effective and safest CAR-T therapy at a more affordable cost. This represents a crucial step towards a smarter, more sustainable approach in cancer treatment, accelerating the transition to a future where advanced cell therapies are widely available and optimally utilized.

Source: https://www.mdc-berlin.de/news/press/making-car-t-cell-therapy-more-effective

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.